Jinghua Pharmaceutical Group Co., Ltd.

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
7.88 ^CNY	+0.13%		+3.55%	-11.16%

Apr. 29	Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 18	Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jinghua Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022

April 24, 2023 at 03:47 pm EDT

Jinghua Pharmaceutical Group Co., Ltd. in its Annual General Meeting of 2022 on 21 April 2023 approved the Cash dividend/10 shares (tax included): CNY 0.80000000.

Latest news about Jinghua Pharmaceutical Group Co., Ltd.

Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe	Apr. 18	MT
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Jinghua Pharmaceutical Group Co., Ltd. Announces Cash Dividend for 2022, Payable on 9 June 2023	23-06-05	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2022	23-04-24	CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022	23-04-24	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-03-30	CI
China COVID infection fears fuel medical stock bets	22-12-12	RE
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Jinghua Pharmaceutical Group Co., Ltd.(XSEC:002349) added to S&P Global BMI Index	22-09-19	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Jinghua Pharmaceutical Group Co., Ltd. Implements 2021 Final Profit Distribution Plan (A Shares), Payable on 13 June 2022	22-06-05	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Profit Distribution for 2021	22-04-25	CI
Jinghua Pharmaceutical's Controlling Shareholder Plans to Cut 2% Stake	22-04-08	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for 2021	22-03-30	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Three Chinese Drugmakers Deny Receiving Orders From Pfizer	22-02-14	MT
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Haian Ruihai Urbanization Investment and Construction Co., Ltd., completed the acquisition of 10.29% stake in Nantong Jinghua Pharmaceutical Co., Ltd. from Zan Shengda.	21-10-18	CI
Jiangsu Qichen New Materials Co., Ltd. acquired 24.9% stake in Jiangsu Wannianchang Pharmaceutical Co., Ltd. from Nantong Jinghua Pharmaceutical Co., Ltd. for CNY 69.4 million.	21-09-28	CI
Nantong Jinghua Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021, Payable 17 September 2021	21-09-03	CI

Chart Jinghua Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Jinghua Pharmaceutical Group Co., Ltd.

More charts

JINGHUA PHARMACEUTICAL GROUP CO., LTD., formerly NANTONG JINGHUA PHARMACEUTICAL CO., LTD., is a China-based company, principally engaged in the research and development, production and distribution of Chinese patent drugs, pharm ingredients and intermediates and chemical intermediates. The Company is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The Company primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The Company offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JINGHUA PHARMACEUTICAL GROUP CO., LTD.	-11.16%	886M
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B